Literature DB >> 455890

Alterations in the disposition of differently cleared drugs in patients with cirrhosis.

U Klotz, C Fischer, P Müller-Seydlitz, J Schulz, W A Müller.   

Abstract

We have compared the disposition of antipyrine orally (15 mg/kg) and the new antiarrhythmic drug lorcainide intravenously (1.5 mg/kg) in 8 patients with alcoholic cirrhosis. Antipyrine (AP) serves as a model drug for drugs which are eliminated independently of liver blood flow and lorcainide (L) elimination as a model for drugs which depend on liver blood flow. Since in healthy subjects elimination half-life (t 1/2) of L increased with age (r = 0.68, p less than 0.01) due to parallel change in the volume of distribution (r = 0.52, p less than 0.05), its disposition had to be compared to age-matched controls. Elimination of both AP and L was impaired in cirrhotic patients, expressed either in terms (mean +/- SD) of t 1/2 (AP = 26.8 +/- 15.0 hr and 12.3 +/- 1.8; L = 12.5 +/- 4.5 hr and 7.7 +/- 2.2 hr, p = 0.002) or of clearance (Cl) (AP = 21.9 +/- 7.9 ml/min and 41.7 +/- 5.5 ml/min; L = 814 +/- 144 and 1002 +/- 304 ml/min, p = 0.06). While the alterations in plasma Cl were great for AP, they were smaller for L. This suggests that elimination of drugs in cirrhotic patients is associated with relatively more impairment of enzyme activity than of hepatic blood flow. The slightly decreased Cl of L in patients with alcoholic cirrhosis would suggest that L should be carefully handled in patients with dysfunction of the liver.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455890     DOI: 10.1002/cpt1979262221

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 2.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 3.  Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  C e Eiriksson; R N Brogden
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

4.  Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.

Authors:  R J Royer; M J Royer-Morrot; F Paille; D Barrucand; J Schmitt; R Defrance; C Salvadori
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

5.  The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.

Authors:  N R Kitteringham; L Büstgens; E Brundert; S Mineshita; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 6.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

Authors:  Robert Hermann; Nassr Nassr; Gezim Lahu; Eva Péterfai; Dietrich Knoerzer; Rolf Herzog; Karl Zech; Christian de Mey
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Elimination of pindolol in liver disease.

Authors:  E E Ohnhaus; U Münch; J Meier
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

Authors:  L A Bauer; T O'Sullivan; W G Reiss; J R Horn; K Opheim; D E Strandness; R L Carithers
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.